AgeX Therapeutics
| Type | Public |
|---|---|
Traded as | AMEX: AGE |
| Industry | Biotechnology, aging research |
| Founded | 2017 |
| Founder | Michael D. West |
| Headquarters | Alameda, California |
Key people | Michael D. West (CEO) Gregory Bailey (chairman) |
| Website | www |
AgeX Therapeutics, Inc. (commonly abbreviated as AgeX Therapeutics or simply AgeX) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others.[1][2][3][4]
The chairman is Gregory Bailey, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.[3][5]
In January 2020, AgeX Therapeutics announced a research collaboration with a Japanese biopharma company utilizing AgeX's UniverCyte technology platform.[6]
External links
References
- ↑ Lawton, Graham (April 24, 2019). "Anti-ageing drugs are coming that could keep you healthier for longer". New Scientist.
- ↑ Wang, Brian (December 16, 2017). "AgeX to develop powerful regenerative and anti-aging treatments". Next Big Future.
- 1 2 Carroll, John (July 26, 2017). "British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart". Endpoints News.
- ↑ "Juvenescence aims to tap longevity 'money fountain'". Financial Times. June 11, 2018.
- ↑ Pollack, Andrew; Picker, Leslie (August 22, 2016). "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal". New York Times.
- ↑ "AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells". Yahoo! Finance. 2020-01-29. Archived from the original on 2020-02-24.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.